WWW.CCOHTA.CA

Canadian Coordinating Office for Health Technology Assessment (CCOHTA)

Common Drug Review *

Submission Status

Product: Lantus

Generic Name: insulin glargine (rDNA origin)

Manufacturer: Aventis Pharma Inc.

Submission Type: NEW

Date Submission Received: 2005-Feb-11 **Date NOC Issued:** 2002-Apr-03

Targeted CEDAC Meeting: 2005-Jun-15 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Deemed Complete	5	2005-Feb-18	2005-Feb-18	
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2005-Apr-25	2005-Apr-29	Additional information requested March 22, 2005. Additional information received March 31, 2005. Additional information requested April 1, 2005. Additional information received April 8 & 12, 2005.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2005-May-04	2005-May-10	Due date for manufacturer's comments May 10, 2005.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2005-May-13	2005-May-24	Due date for reviewer's reply May 19, 2005.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2005-Jun-01	2005-Jun-02	
6	CEDAC Meeting		2005-Jun-15	2005-Jun-15	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2005-Jun-22	2005-Jun-22	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2005-Jul-07	2005-Jul-29	Request for extension of Embargo Period received on June 29, 2005. Extension approved, new end date for Embargo Period is July 29, 2005. Request for reconsideration received July 29, 2005. Additional information requested August 19, 2005. Additional information received August 25, 2005.
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates	2005-Sep-21	2005-Sep-21	
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5	2005-Sep-28	2005-Sep-28	Notice of Final Recommendation Issued.

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.ccohta.ca for more details.
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.ccohta.ca.
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.